GlassScriptPhysician profile
Laura L Keys
NPI 1124367644
$2,369.27
in general payments reported to CMS, 2019-2025
41 companies · $1,832 in 2025
The $1,832 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.41 · 2023: $35.13 · 2024: $454 · 2025: $1,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,321.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $209.03 | 2024-2025 | |
| Genentech USA, INC. | $194.92 | 2024-2025 | Venclexta, Tecentriq, Polivy |
| Merck Sharp & Dohme LLC | $193.56 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $126.14 | 2024-2025 | Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $118.55 | 2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $101.59 | 2024-2025 | Tecvayli, Darzalex |
| Gilead Sciences, INC. | $97.53 | 2024-2025 | Trodelvy |
| Astellas Pharma US INC | $94.87 | 2024-2025 | Vyloy, Padcev, Xtandi |
| Stemline Therapeutics INC. | $94.54 | 2024-2025 | Orserdu |
| Beigene USA, INC. | $81.78 | 2024-2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $79.19 | 2024-2025 | Ninlaro, Iclusig |
| Abbvie INC. | $73.96 | 2021-2025 | |
| Pfizer INC. | $71.02 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $67.76 | 2024-2025 | Onivyde, Somatuline Depot |
| Celgene Corporation | $65.32 | 2025 | Reblozyl, Opdualag |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $56.45 | 2025 | Jakafi, Monjuvi, Niktimvo |
| Emd Serono, INC. | $54.72 | 2025 | |
| Lilly USA, LLC | $51.08 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Exelixis INC. | $49.33 | 2024-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $40.81 | 2025 | |
| Radius Health, INC. | $35.13 | 2023 | Tymlos |
| Genzyme Corporation | $34.71 | 2025 | |
| Tersera Therapeutics LLC | $34.04 | 2025 | Zoladex |
| Karyopharm Therapeutics INC. | $33.70 | 2025 | Xpovio |
| Sobi, INC | $27.31 | 2024 | |
| Deciphera Pharmaceuticals INC. | $23.06 | 2025 | Romvimza, Qinlock |
| Aveo Pharmaceuticals, INC. | $19.92 | 2024 | |
| Jazz Pharmaceuticals INC. | $19.90 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $19.43 | 2025 | Libtayo |
| Kite Pharma, INC. | $19.07 | 2025 | Yescarta |
| Array Biopharma INC | $18.44 | 2025 | Braftovi, Lorbrena, Mektovi |
| E.R. Squibb & Sons, L.L.C. | $18.00 | 2025 | Opdivo |
| Glaxosmithkline, LLC. | $17.13 | 2025 | Ojjaara |
| Agios Pharmaceuticals, INC. | $17.08 | 2025 | Pyrukynd |
| Beone Medicines USA, INC. | $16.62 | 2025 | Brukinsa |
| Genmab U.S., INC. | $16.55 | 2024 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.26 | 2025 | |
| Legend Biotech USA INC. | $15.87 | 2025 | Carvykti |
| Azurity Pharmaceuticals, INC. | $15.01 | 2025 | Danziten |
| Pharming Healthcare, INC. | $14.97 | 2024 | Ruconest |
| Novocure INC. | $14.92 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Keys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.